Overview

Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness

Status:
Unknown status
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
The Purpose of this study is to predict antidepressant response in advance using pharmacogenomics and peripheral biological markers in depressed patients.
Phase:
N/A
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Antidepressive Agents
Bupropion
Citalopram
Duloxetine Hydrochloride
Fluoxetine
Mirtazapine
Nortriptyline
Paroxetine
Sertraline
Trazodone
Venlafaxine Hydrochloride